ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.40
+0.15 (1.82%)
At close: Aug 27, 2026, 4:00 PM EDT
8.41
+0.01 (0.12%)
After-hours: Aug 27, 2026, 7:59 PM EDT
ImmunityBio Market Cap
ImmunityBio has a market cap or net worth of $8.9 billion as of August 27, 2026. Its market cap has increased by 295.72% in one year.
Market Cap
8.90B
Enterprise Value
9.77B
1-Year Change
295.72%
Ranking
Category
Stock Price
$8.40
ChartMarket Cap Chart
Since March 10, 2021, ImmunityBio's market cap has decreased from $14.82B to $8.90B, a decrease of -39.94%. That is a compound annual growth rate of -8.90%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 27, 2026 | 8.90B | 356.49% |
| Dec 31, 2025 | 1.95B | 4.33% |
| Dec 31, 2024 | 1.87B | -44.23% |
| Dec 29, 2023 | 3.35B | 61.49% |
| Dec 30, 2022 | 2.08B | -14.18% |
| Dec 31, 2021 | 2.42B | -83.68% |
| Mar 10, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Kymera Therapeutics | 10.53B |
| Praxis Precision Medicines | 10.28B |
| Apogee Therapeutics | 10.17B |
| Protagonist Therapeutics | 9.74B |
| Spyre Therapeutics | 9.47B |
| Vaxcyte | 9.09B |
| Crinetics Pharmaceuticals | 9.00B |
| Immunovant | 8.99B |